Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
iBio, Inc. stock logo
IBIO
iBio
$1.43
-2.7%		$1.51
$0.74
▼
$3.82
$73.03M1.3801,651 shs754,676 shs
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$1.16
+3.1%		$1.11
$1.02
▼
$1.95
$69.35M1.24414,743 shs504,685 shs
Palatin Technologies stock logo
PTN
Palatin Technologies
$9.69
-5.0%		$9.64
$5.61
▼
$31.00
$17.25M0.6320,531 shs4,495 shs
XBiotech Inc. stock logo
XBIT
XBiotech
$2.28
-1.3%		$2.30
$2.09
▼
$3.61
$70.43M0.8426,853 shs11,043 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
iBio, Inc. stock logo
IBIO
iBio
-2.72%0.00%+3.62%-22.28%+142,999,900.00%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
+3.12%+7.94%+5.00%-4.55%-19.23%
Palatin Technologies stock logo
PTN
Palatin Technologies
-5.00%+3.53%+18.90%-34.88%+968,999,900.00%
XBiotech Inc. stock logo
XBIT
XBiotech
-1.30%-0.87%+0.44%-6.17%-29.19%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
iBio, Inc. stock logo
IBIO
iBio
$1.43
-2.7%		$1.51
$0.74
▼
$3.82
$73.03M1.3801,651 shs754,676 shs
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$1.16
+3.1%		$1.11
$1.02
▼
$1.95
$69.35M1.24414,743 shs504,685 shs
Palatin Technologies stock logo
PTN
Palatin Technologies
$9.69
-5.0%		$9.64
$5.61
▼
$31.00
$17.25M0.6320,531 shs4,495 shs
XBiotech Inc. stock logo
XBIT
XBiotech
$2.28
-1.3%		$2.30
$2.09
▼
$3.61
$70.43M0.8426,853 shs11,043 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
iBio, Inc. stock logo
IBIO
iBio
-2.72%0.00%+3.62%-22.28%+142,999,900.00%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
+3.12%+7.94%+5.00%-4.55%-19.23%
Palatin Technologies stock logo
PTN
Palatin Technologies
-5.00%+3.53%+18.90%-34.88%+968,999,900.00%
XBiotech Inc. stock logo
XBIT
XBiotech
-1.30%-0.87%+0.44%-6.17%-29.19%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
iBio, Inc. stock logo
IBIO
iBio
3.13
Buy$5.00249.65% Upside
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
1.75
Reduce$3.00159.74% Upside
Palatin Technologies stock logo
PTN
Palatin Technologies
3.00
Buy$55.00467.60% Upside
XBiotech Inc. stock logo
XBIT
XBiotech
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest PTN, IBIO, PLRX, and XBIT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2026
XBiotech Inc. stock logo
XBIT
XBiotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/2/2026
iBio, Inc. stock logo
IBIO
iBio
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
6/30/2026
XBiotech Inc. stock logo
XBIT
XBiotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/24/2026
iBio, Inc. stock logo
IBIO
iBio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/12/2026
XBiotech Inc. stock logo
XBIT
XBiotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/8/2026
iBio, Inc. stock logo
IBIO
iBio
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$5.00
6/8/2026
iBio, Inc. stock logo
IBIO
iBio
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$5.00
6/5/2026
iBio, Inc. stock logo
IBIO
iBio
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$6.00
(Data available from 8/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
iBio, Inc. stock logo
IBIO
iBio
$400K177.61N/AN/A$0.90 per share1.59
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$1.58M45.26N/AN/A$2.37 per share0.49
Palatin Technologies stock logo
PTN
Palatin Technologies
$4.49M3.84N/AN/A$5.95 per share1.63
XBiotech Inc. stock logo
XBIT
XBiotech
N/AN/AN/AN/A$4.21 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
iBio, Inc. stock logo
IBIO
iBio
-$18.38M-$0.58N/AN/AN/AN/A-53.86%-46.48%9/4/2026 (Estimated)
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-$149.34M-$1.49N/AN/AN/AN/A-52.17%-40.46%11/5/2026 (Estimated)
Palatin Technologies stock logo
PTN
Palatin Technologies
-$17.31MN/AN/AN/AN/AN/A-141.40%-58.08%9/2/2026 (Estimated)
XBiotech Inc. stock logo
XBIT
XBiotech
-$45.54M-$1.48N/AN/AN/AN/A-31.62%-30.29%N/A

Latest PTN, IBIO, PLRX, and XBIT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/4/2026Q4 2026
iBio, Inc. stock logo
IBIO
iBio
-$0.07N/AN/AN/A$0.08 millionN/A
9/2/2026Q4 2026
Palatin Technologies stock logo
PTN
Palatin Technologies
-$1.20N/AN/AN/A$1.50 millionN/A
8/13/2026Q2 2026
XBiotech Inc. stock logo
XBIT
XBiotech
$0.03-$0.22-$0.25-$0.22$7.00 millionN/A
8/11/2026Q2 2026
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-$0.3418-$0.36-$0.0182-$0.36N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
iBio, Inc. stock logo
IBIO
iBio
N/AN/AN/AN/AN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
N/AN/AN/AN/AN/A
Palatin Technologies stock logo
PTN
Palatin Technologies
N/AN/AN/AN/AN/A
XBiotech Inc. stock logo
XBIT
XBiotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
iBio, Inc. stock logo
IBIO
iBio
N/A
11.88
11.88
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
N/A
9.90
9.90
Palatin Technologies stock logo
PTN
Palatin Technologies
N/A
5.04
5.04
XBiotech Inc. stock logo
XBIT
XBiotech
N/A
33.15
33.15

Institutional Ownership

CompanyInstitutional Ownership
iBio, Inc. stock logo
IBIO
iBio
7.90%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
97.30%
Palatin Technologies stock logo
PTN
Palatin Technologies
11.50%
XBiotech Inc. stock logo
XBIT
XBiotech
55.70%

Insider Ownership

CompanyInsider Ownership
iBio, Inc. stock logo
IBIO
iBio
2.75%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
8.74%
Palatin Technologies stock logo
PTN
Palatin Technologies
7.10%
XBiotech Inc. stock logo
XBIT
XBiotech
30.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
iBio, Inc. stock logo
IBIO
iBio
10049.68 million48.31 millionN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
9061.92 million56.51 millionOptionable
Palatin Technologies stock logo
PTN
Palatin Technologies
301.78 million1.65 millionN/A
XBiotech Inc. stock logo
XBIT
XBiotech
10030.49 million21.10 millionOptionable

Recent News About These Companies

XBiotech (NASDAQ:XBIT) Issues Quarterly Earnings Results, Misses Estimates By $0.25 EPS
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/xbiotech-nasdaqxbit-issues-quarterly-earnings-results-misses-estimates-by-025-eps-2026-08-13/
XBiotech (NASDAQ:XBIT) Share Price Crosses Below 200-Day Moving Average - What's Next?
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/xbiotech-nasdaqxbit-share-price-crosses-below-200-day-moving-average-whats-next-2026-07-30/
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
June 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/15/3311812/35550/en/xbiotech-launches-phase-ii-clinical-trial-evaluating-vilamakitug-for-the-treatment-of-active-axial-spondyloarthritis.html
XBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ Radar
May 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/xbiotechs-new-axial-spondyloarthritis-trial-puts-vilamakitug-on-investors-radar?utm_source=marketbeat.com&utm_medium=referral
XBiotech: Q4 Earnings Snapshot
March 13, 2026  |  chron.comhttps://www.chron.com/business/article/xbiotech-q4-earnings-snapshot-22075535.php
XBiotech’s New Trial: A Potential Game-Changer for Rheumatoid Arthritis Treatment?
October 28, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/xbiotech-s-new-trial-a-potential-game-changer-for-rheumatoid-arthritis-treatment/ar-AA1PitPW
XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insiders
August 28, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/xbiotech-inc-nasdaq-xbit-top-100425873.html
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
March 2, 2025  |  accessnewswire.comA
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
March 1, 2025  |  accessnewswire.comA
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
February 28, 2025  |  accessnewswire.comA
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
February 27, 2025  |  accessnewswire.comA
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
February 26, 2025  |  accessnewswire.comA
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
February 25, 2025  |  accessnewswire.comA
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
February 24, 2025  |  accessnewswire.comA
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
February 23, 2025  |  accessnewswire.comA
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
February 22, 2025  |  accessnewswire.comA
An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
February 21, 2025  |  accessnewswire.comA
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
February 20, 2025  |  accessnewswire.comA
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
February 18, 2025  |  accessnewswire.comA
XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
February 17, 2025  |  accessnewswire.comA
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation
February 16, 2025  |  accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

iBio stock logo

iBio NASDAQ:IBIO

$1.43 -0.04 (-2.72%)
As of 08/21/2026 04:00 PM Eastern

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Pliant Therapeutics stock logo

Pliant Therapeutics NASDAQ:PLRX

$1.16 +0.04 (+3.13%)
As of 08/21/2026 04:00 PM Eastern

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Palatin Technologies stock logo

Palatin Technologies NYSEAMERICAN:PTN

$9.69 -0.51 (-5.00%)
As of 08/21/2026 04:00 PM Eastern

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

XBiotech stock logo

XBiotech NASDAQ:XBIT

$2.28 -0.03 (-1.30%)
As of 08/21/2026 04:00 PM Eastern

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas